Home » Newsletters » BioWorld Science

BioWorld Science

May 27, 2013

View Archived Issues

Phase I data presented for RPC-1063 in IBD patients

Complementary biomarker for the diagnosis of gastrointestinal carcinoma described

Partnership to advance fusion protein for NHL

Results presented for Pulmagen's lead oral DP2 receptor antagonist ADC-3680

Blood thiamine metabolism as a non-invasive biomarker for AD diagnosis

HGT-1410 demonstrates rapid systemic distribution in vivo

New inhibitors of phosphate transport synthesized by Astellas

Merck & Co. patents novel GPR119 receptor agonists

Canadian group discloses new CBX2 modulators for cancer

Novel FABP inhibitors divulged by Roche

Merck & Co. presents novel bacterial vaccines

Companies announce termination of QVAR comarketing agreement

Rigel Pharmaceuticals set to advance to phase II trial for dry eye disease therapeutic

Scientists at Merck & Co. synthesize novel gamma-secretase modulators

HbA1c test receives marketing approval in U.S. for diabetes diagnosis

TauRx Therapeutics opens U.K. sites in phase III trials of LMTX

Bayer Yakuhin launches Stivarga tablets in Japan

Merck & Co. discontinues development of preladenant for Parkinson's disease

PharmaMar studies PM-01183 in combination with capecitabine

Nippon Shinyaku launches Regtect in Japan

Mitsubishi Tanabe Pharma seeks Japanese approval of canagliflozin

OncoTherapy Science obtains rights to results of collaborative research with Kumamoto University

Data show GCS-100 may improve renal function

Astellas submits marketing application in Japan for enzalutamide

Dosing begins in phase I trial of SB-9200 in HCV infection

Headline results reported from phase IIIa trial of liraglutide for obesity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial
BioWorld
Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...
Neuro deals aplenty: UCB’s $1B+ takeover of Neurona the latest
BioWorld
A flurry of deals focused on the neurological disease space in 2026 suggest large biopharma companies are searching for the next best therapeutics for everything...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...